Levosimendan

Drug Profile

Levosimendan

Alternative Names: Daxim; ODM 109; OR-1259; Oral levosimendan - Orion; Simdax

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Orion
  • Developer Abbott Laboratories; AbbVie; Imperial College of Science, Technology and Medicine; Orion; Tenax Therapeutics
  • Class Antiarrhythmics; Cardiotonics; Hydrazones; Nitriles; Pyridazines; Small molecules; Vasodilators
  • Mechanism of Action Calcium-binding protein modulators; Calcium-sensitising phosphodiesterase inhibitors; Potassium channel agonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute heart failure
  • Phase III Low cardiac output
  • Phase II Amyotrophic lateral sclerosis
  • Discontinued Chronic heart failure; Myocardial infarction; Septic shock; Stroke; Transient ischaemic attacks

Most Recent Events

  • 19 Mar 2017 Adverse events and efficacy data from the phase III LEVO-CTS trial in Low cardiac output released by Tenax Therapeutics
  • 08 Feb 2017 Orion completes a phase II trial in Amyotrophic lateral sclerosis in United Kingdom, Germany, Ireland and Netherlands (NCT02487407)
  • 31 Jan 2017 Tenax therapeutics announced its plans to meet with the US FDA to discuss preliminary results of the phase III LEVO-CTS study and future development steps
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top